Cargando…

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

With the demographic shift of the global population toward longer life expectancy, the number of people living with Alzheimer’s disease (AD) has rapidly expanded and is projected to triple by the year 2050. Current treatments provide symptomatic relief but do not affect the underlying pathology of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritter, Aaron, Cummings, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553391/ https://www.ncbi.nlm.nih.gov/pubmed/26379620 http://dx.doi.org/10.3389/fneur.2015.00186

Ejemplares similares

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer’s Disease
por: Aksnes, Mari, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
por: Bjorkli, Christiana, et al.
Publicado: (2020)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)

The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer’s Disease: Exploring Interactions With Sex
por: Liu, Ying, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease
por: Mumtaz, Ibtisam, et al.
Publicado: (2022)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Biomarkers in Alzheimer’s Disease
por: Riverol, Mario, et al.
Publicado: (2011)

Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2020
por: Cummings, Jeffrey, et al.
Publicado: (2020)

Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience
por: Ritter, Aaron, et al.
Publicado: (2018)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
por: Llorens, Franc, et al.
Publicado: (2017)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Clinical significance of fluid biomarkers in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2020)

Current state of Alzheimer’s fluid biomarkers
por: Molinuevo, José Luis, et al.
Publicado: (2018)

Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
por: Cummings, Jeffrey, et al.
Publicado: (2022)

An atlas on biomarkers for Alzheimer's disease
por: Martínez-Rivera, Marta
Publicado: (2013)

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
por: Kang, Ju-Hee, et al.
Publicado: (2014)

Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease
por: Xu, Yanan, et al.
Publicado: (2023)

Brain Atrophy and Clinical Characterization of Adults With Mild Cognitive Impairment and Different Cerebrospinal Fluid Biomarker Profiles According to the AT(N) Research Framework of Alzheimer’s Disease
por: Rivas-Fernández, Miguel Ángel, et al.
Publicado: (2022)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

The Eye As a Biomarker for Alzheimer's Disease
por: Lim, Jeremiah K. H., et al.
Publicado: (2016)

Electrophysiological Biomarkers of Epileptogenicity in Alzheimer’s Disease
por: Yu, Tingting, et al.
Publicado: (2021)

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
por: Cummings, Jeffrey
Publicado: (2017)

Changes in Adiposity and Cerebrospinal Fluid Biomarkers Following a Modified Mediterranean Ketogenic Diet in Older Adults at Risk for Alzheimer’s Disease
por: Brinkley, Tina E., et al.
Publicado: (2022)

The Role of Non-coding RNAs in Alzheimer’s Disease: From Regulated Mechanism to Therapeutic Targets and Diagnostic Biomarkers
por: Zhang, Yuan, et al.
Publicado: (2021)

Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer’s Disease: The Paradigmatic Example of CSF
por: Canevelli, Marco, et al.
Publicado: (2019)

Statistical advances in clinical trials and clinical research
por: Shan, Guogen, et al.
Publicado: (2018)

Editorial: Biomarkers of Alzheimer’s Disease: The Present and the Future
por: Lehmann, Sylvain, et al.
Publicado: (2016)

Ophthalmic Biomarkers for Alzheimer’s Disease: A Review
por: Majeed, Ayesha, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer’s Disease Patients
por: Spuch, Carlos, et al.
Publicado: (2015)

Reduction of Glycolysis Intermediate Concentrations in the Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Bergau, Nick, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iun7mat7bi6ie9u3ii1var07hc